Product Description
a novel antimalarial drug with a novel mode of action (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34798913/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Malaria|Malaria, Falciparum
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AC-071-102 | P1 |
Completed |
Malaria, Falciparum |
2014-07-01 |
|
| AC-071-101 | P1 |
Completed |
Malaria |
2012-04-01 |
28% |
| ACTRN12614000781640 | P1 |
Active, not recruiting |
Malaria |
None |